Neuronetics, Inc. provided earnings guidance for the second quarter of fiscal year 2024. For the quarter, the company expects total worldwide revenue between $18.0 million and $19.0 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.79 USD | -1.65% | -13.11% | -38.28% |
May. 15 | Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents | CI |
May. 14 | William Blair Upgrades Neuronetics to Outperform From Market Perform | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.28% | 53.7M | |
+4.98% | 213B | |
+7.44% | 184B | |
+28.22% | 153B | |
+33.19% | 113B | |
+0.49% | 63.66B | |
+16.51% | 53.53B | |
+1.45% | 49.11B | |
-4.53% | 38.73B | |
+2.74% | 36.26B |
- Stock Market
- Equities
- STIM Stock
- News Neuronetics, Inc.
- Neuronetics, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal Year 2024